The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
Open accessThe DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are usually associated with loss of dopaminergic neurons. Loss of substantia nigra neurons and presence of Lewy body inclusions in some of the remaining neurons are the hallmark pathology seen in the final stages of the disease. Attempts to correlate Lewy body pathology to either cell death or severity of clinical symptoms, however, have not been successful. While the pathophysiology of the neurodegenerative process can hardly be explained by Lewy bodies, the clinical symptoms do indicate a degenerative process located at the presynapse resulting in a neurotransmitter deficiency. Recently it was shown that 90% or even more of alpha-synuclein aggregates in DLB cases were located at the presynapses in the form of very small deposits. In parallel, dendritic spines are retracted, whereas the presynapses are relatively preserved, suggesting a neurotransmitter deprivation. The same alpha-synuclein pathology can be demonstrated for PD. These findings give rise to the notion that not cell death but rather alpha-synuclein aggregate-related synaptic dysfunction causes the neurodegeneration. This opens new perspectives for understanding PD and DLB. If presynaptic alpha-synuclein aggregation, not neuronal loss, is the key issue of the neurodegenerative process, then PD and DLB may eventually be treatable in the future. The disease may progress via trans-synaptical spread, suggesting that stem cell transplants are of limited use. Future therapies may focus on the regeneration of synapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD is associated with four cardinal motor symptoms, including tremors, rigidity, bradykinesia, and postural instability, alongside the characteristic shuffling and stooped posture of the “Parkinsonian gait” [46].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“It could be demonstrated that the presence of symptoms may be related to the involvement of defined regions as measured by the occurrence of Lewy bodies [47–49], supporting the observations that the a-synuclein aggregation pathology spreads through the brain involving anatomical structures sequentially [13].”
BackgroundAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“The discovery of mutations in the a-synuclein gene [77, 114, 156] and overexpression of a-synuclein [123] as being associated with Parkinson’s disease or dementia with Lewy bodies (DLB) strengthens the association between protein”
BackgroundParkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 2×
“Tremor at rest, rigidity, akinesia/bradykinesia and postural instability are the four cardinal features in Parkinson’s disease [60].”
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“association between the frequency and extension of tangles and Ab-plaques and the occurrence of the disease [55, 104], Terry et al.”
BackgroundChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“It was assumed that the cognitive impairment in AD is related to a synaptic failure [121, 124, 130].”
Background
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
The many faces of α-synuclein: from structure and toxicity to therapeutic target
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3406 · Cited by 1,622
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
“Similar to AD, protein misfolding also occurs in PD [45], and the protein that is commonly misfolded is the tau protein.”
BackgroundMDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
Litvan, I., Aarsland, D., Adler, C. H., Goldman, J. G., Kulisevsky, J., Mollenhauer, B., Rodriguez‐Oroz, M. C., Tröster, A. I., & Weintraub, D. (2011) · Movement Disorders · doi:10.1002/mds.23823 · Cited by 805
Parkinson's Disease and Parkinsonism: Neuropathology
Dickson, D. W. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009258 · Cited by 847
“…because it is increasingly clear that abnormal a-synuclein accumulation in neuronal perikarya may be the tip of the iceberg, with evidence of accumulation not only in neuronal cell processes (Irizarry et al. 1998), but also with the synaptic compartment (Muntane et al. 2008; Schulz-Schaeffer 2010).”
BackgroundBDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
Self-citationMiñones-Moyano, E., Porta, S., Escaramís, G., Rabionet, R., Iraola, S., Kagerbauer, B., Espinosa-Parrilla, Y., Ferrer, I., Estivill, X., & Martí, E. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr210 · Cited by 482
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease
Gray, M. T., & Woulfe, J. M. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.32 · Cited by 409
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 385
Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
Bridi, J. C., & Hirth, F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00080 · Cited by 378
“This often occurs concomitantly with the manifestation of cognitive symptoms, with a neuronal degeneration emerging at later stages of disease (Milnerwood and Raymond, 2010; Schulz-Schaeffer, 2010; Picconi et al., 2012).”
BackgroundCircadian Rhythms, Sleep, and Disorders of Aging
Mattis, J., & Sehgal, A. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.02.003 · Cited by 369
“Pathologically, PD is characterized by loss of midbrain dopaminergic neurons and by abnormal accumulation of the protein alpha-synuclein into intraneuronal inclusions called Lewy bodies [80].”
BackgroundAlpha-synuclein oligomers: a new hope
Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1755-1 · Cited by 338
“Images adapted from SchulzSchaeffer [138], with permission from the publisher.”
BackgroundMethodInfluentialKovacs, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020189 · Cited by 321
“For PD and DLB only Lewy bodies and neurites are evaluated for diagnostic classifications.”
MethodInfluentialDopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Alpha-synuclein: from secretion to dysfunction and death
Marques, O., & Outeiro, T. F. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.94 · Cited by 286
α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B
Ferreira, D. G., Temido-Ferreira, M., Vicente Miranda, H., Batalha, V. L., Coelho, J. E., Szegö, É. M., Marques-Morgado, I., Vaz, S. H., Rhee, J. S., Schmitz, M., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4648 · Cited by 278
Synaptic Dysfunction in Parkinson’s Disease
Picconi, B., Piccoli, G., & Calabresi, P. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_24 · Cited by 290
“Intracytoplasmic inclusions called Lewy bodies and the progressive loss of DA-containing neurons in the SNc represent the main neuropathological features of the genetic forms of PD (Spillantini et al. 1998; Dickson et al. 2009; Schulz-Schaeffer, 2010).”
Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J. (2015) · Brain · doi:10.1093/brain/awv040 · Cited by 271
“Dysfunction at synapses and altered axonal transport has been postulated to be some of the earliest pathological events in Parkinson’s disease (Schulz-Schaeffer, 2010; Kim-Han et al., 2011; Nakata et al., 2012).”
BackgroundDementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
“2016; Schulz-Schaeffer 2010; Seidel et al.”
BackgroundIntegrating Pathways of Parkinson's Disease in a Molecular Interaction Map
Fujita, K. A., Ostaszewski, M., Matsuoka, Y., Ghosh, S., Glaab, E., Trefois, C., Crespo, I., Perumal, T. M., Jurkowski, W., Antony, P. M. A., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8489-4 · Cited by 273
“Also, α-syn forms potentially pathogenic microaggregates in the synapse [60].”
BackgroundCognitive impairment and dementia in Parkinson's disease
Pagonabarraga, J., & Kulisevsky, J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.029 · Cited by 257
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis
Donaghy, P. C., & McKeith, I. G. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt274 · Cited by 249
“Presynaptic accumulation of αSyn and resultant synaptic dysfunction has been put forward as a causative factor of neurodegeneration in LB disease but, like LB deposition, this cannot yet be measured in vivo [41].”
BackgroundGaspar, R., Meisl, G., Buell, A. K., Young, L., Kaminski, C. F., Knowles, T. P. J., Sparr, E., & Linse, S. (2017) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583516000172 · Cited by 249
Hiscox, L. V., Johnson, C. L., Barnhill, E., McGarry, M. D. J., Huston, J., van Beek, E. J. R., Starr, J. M., & Roberts, N. (2016) · Physics in Medicine and Biology · doi:10.1088/0031-9155/61/24/r401 · Cited by 230
World Journal of Pharmaceutical Sciences
(2021) · World Journal of Pharmaceutical Sciences · doi:10.54037/wjps · Cited by 245
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Rockenstein, E., Nuber, S., Overk, C. R., Ubhi, K., Mante, M., Patrick, C., Adame, A., Trejo-Morales, M., Gerez, J., Picotti, P., et al. (2014) · Brain · doi:10.1093/brain/awu057 · Cited by 238
RetractedExpanding the spectrum of neuronal pathology in multiple system atrophy
Cykowski, M. D., Coon, E. A., Powell, S. Z., Jenkins, S. M., Benarroch, E. E., Low, P. A., Schmeichel, A. M., & Parisi, J. E. (2015) · Brain · doi:10.1093/brain/awv114 · Cited by 241
Zhang, J., Li, X., & Li, J.-D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00381 · Cited by 210
“Synaptic dysfunction is an early pathological feature of PD (Schulz-Schaeffer, 2010).”
BackgroundDu, X., & Pang, T. Y. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00032 · Cited by 205
Brain iron deposition is linked with cognitive severity in Parkinson’s disease
Thomas, G. E. C., Leyland, L. A., Schrag, A.-E., Lees, A. J., Acosta-Cabronero, J., & Weil, R. S. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322042 · Cited by 211
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
Boeve, B. F. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70054-1 · Cited by 199
Review: Parkinson's disease: from synaptic loss to connectome dysfunction
Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., & Spano, P. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12297 · Cited by 206
Stage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease
Dijkstra, A. A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Bank, N. B., Rozemuller, A. J. M., & van de Berg, W. D. J. (2014) · Movement Disorders · doi:10.1002/mds.25952 · Cited by 176
Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias
Colloby, S. J., McParland, S., O'Brien, J. T., & Attems, J. (2012) · Brain · doi:10.1093/brain/aws211 · Cited by 188
Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging
Matuskey, D., Tinaz, S., Wilcox, K. C., Naganawa, M., Toyonaga, T., Dias, M., Henry, S., Pittman, B., Ropchan, J., Nabulsi, N., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25682 · Cited by 180
Neuropathobiology of non-motor symptoms in Parkinson disease
Jellinger, K. A. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1405-5 · Cited by 176
“…protein aggregated in neurons, neurites, presynaptic terminals and glia and a hallmark in PD and other synucleinopathies (Jellinger 2012b, c, 2014; Schulz-Schaeffer 2010; Spil- lantini et al. 1997). aSyn aggregation that predates the formation of Lewy bodies (LB) and dystrophic neurites…”
BackgroundNeuropathology of multiple system atrophy: New thoughts about pathogenesis
Jellinger, K. A. (2014) · Movement Disorders · doi:10.1002/mds.26052 · Cited by 181
Kovacs, G. G., Wagner, U., Dumont, B., Pikkarainen, M., Osman, A. A., Streichenberger, N., Leisser, I., Verchère, J., Baron, T., Alafuzoff, I., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0964-x · Cited by 169
Synaptic pathology: A shared mechanism in neurological disease
Henstridge, C. M., Pickett, E., & Spires-Jones, T. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.005 · Cited by 174
Batool, S., Raza, H., Zaidi, J., Riaz, S., Hasan, S., & Syed, N. I. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00833.2018 · Cited by 163
“An elegant series of experiments where truncated pre- and postsynaptic GCs from the Lymnaea neurons (labeled as “growth balls”) were demonstrated to exhibit synapse formation immediately upon contact, these nascent “synapses” were however only short lived (Schulz-Schaeffer 2010).”
BackgroundSalivary biomarkers for the diagnosis and monitoring of neurological diseases
Farah, R., Haraty, H., Salame, Z., Fares, Y., Ojcius, D. M., & Said Sadier, N. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.03.004 · Cited by 170
Adult neurogenesis and neurodegenerative diseases: A systems biology perspective
Horgusluoglu, E., Nudelman, K., Nho, K., & Saykin, A. J. (2017) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32429 · Cited by 174
“The accumulation of a-synuclein as the major component of Lewy bodies and Lewy neurites is the pathological hallmark of PD [Schulz-Schaeffer, 2010].”
BackgroundOksanen, M., Lehtonen, S., Jaronen, M., Goldsteins, G., Hämäläinen, R. H., & Koistinaho, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03111-7 · Cited by 153
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities
Berg, D., Lang, A. E., Postuma, R. B., Maetzler, W., Deuschl, G., Gasser, T., Siderowf, A., Schapira, A. H., Oertel, W., Obeso, J. A., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70047-4 · Cited by 158
Lazzaro, V. D., Bella, R., Benussi, A., Bologna, M., Borroni, B., Capone, F., Chen, K.-H. S., Chen, R. E., Chistyakov, A. V., Claßen, J., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.05.035 · Cited by 173
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163
The role of neuroimaging in Parkinson’s disease
Bidesi, N., Andersen, I. V., Windhorst, A. D., Shalgunov, V., & Herth, M. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15516 · Cited by 171
Synaptic dysfunction in Parkinson's disease
Bagetta, V., Ghiglieri, V., Sgobio, C., Calabresi, P., & Picconi, B. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380493 · Cited by 160
Peterson, C. T. (2020) · Journal of Evidence-Based Integrative Medicine · doi:10.1177/2515690x20957225 · Cited by 160
Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease
Parkkinen, L., O'Sullivan, S. S., Collins, C., Petrie, A., Holton, J. L., Revesz, T., & Lees, A. J. (2011) · Journal of Parkinson's Disease · doi:10.3233/jpd-2011-11046 · Cited by 149
“[34, 35].”
Walker, D. G., Lue, L.-F., Adler, C. H., Shill, H. A., Caviness, J. N., Sabbagh, M. N., Akiyama, H., Serrano, G. E., Sue, L. I., & Beach, T. G. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.11.020 · Cited by 152
“…87 and tyrosine 125 (Chen et al, 2009; Paleologou et al, 2010), but the pathological significance of pS129-α-synuclein modification has been the most widely investigated (Anderson et al, 2006; Beach et al, 2010; Cavallarin et al, 2010; Sato et al, 2011; Schulz-Schaeffer 2010; Sugeno et al, 2008).”
BackgroundNeuropathology of incidental Lewy body & prodromal Parkinson’s disease
Koeglsperger, T., Rumpf, S.-L., Schließer, P., Struebing, F. L., Brendel, M., Levin, J., Trenkwalder, C., Höglinger, G. U., & Herms, J. W. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00622-7 · Cited by 159
“Although this concept has not been examined in iLBD, it suggests that the traditional neuropathological staging (assessing somatic LBs) may not capture the true onset or progression of LBP, thus limiting its validity [95, 130, 223].”
BackgroundCellular models for Parkinson's disease
Falkenburger, B. H., Saridaki, T., & Dinter, E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13618 · Cited by 165
“Yet, they most likely cause synaptic dysfunction since a loss of synaptic spines has been observed in brain areas with extensive Lewy pathology (Schulz-Schaeffer 2010).”
BackgroundExploring the link between glucocerebrosidase mutations and parkinsonism
Westbroek, W., Gustafson, A. M., & Sidransky, E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.003 · Cited by 145
Expression pattern and localization of alpha-synuclein in the human enteric nervous system
Böttner, M., Zorenkov, D., Hellwig, I., Barrenschee, M., Harde, J., Fricke, T., Deuschl, G., Egberts, J.-H., Becker, T., Fritscher-Ravens, A., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.07.018 · Cited by 139
“3, 24105 Kiel, Germany Abbreviations: α-syn, α-synuclein; p-α-syn, phosph teric nervous system; CNS, central nervous system; LB, L LMD, laser microdissection; GI, gastrointestinal; PD, Par tative PCR. ⁎ Corresponding author at: Department of Anatomy, in Kiel, Otto-Hahn-Platz 8, D-24118 Kiel, Germany.”
InfluentialBeyer, K., & Ariza, A. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8330-5 · Cited by 157
The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease
Gorenberg, E. L., & Chandra, S. S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00248 · Cited by 140
“It has also been noted that synapses are enriched in proteins susceptible to misfolding and aggregation, such as α-synuclein, tau, and amyloid-β, all of which are linked to neurodegenerative diseases (Schubert et al., 1991; Fortin et al., 2004; Kramer and Schulz-Schaeffer, 2007; Greten-Harrison et al., 2010; Schulz-Sc…”
BackgroundThe role of DNA repair in brain related disease pathology
Canugovi, C., Misiak, M., Ferrarelli, L. K., Croteau, D. L., & Bohr, V. A. (2013) · DNA Repair · doi:10.1016/j.dnarep.2013.04.010 · Cited by 135
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Zarkali, A., Thomas, G. E. C., Zetterberg, H., & Weil, R. S. (2024) · Nature Communications · doi:10.1038/s41467-024-49949-9 · Cited by 147
“…with cognitive severity 250 and may have applications in PD. Recently, PET ligands binding to synaptic vesicle 2a (SV2a), such as 11C-UCB-J, have been developed, providing a in vivo marker of synaptic density, thought to be a key pathomechanism in PD and PD progression to dementia 251 .”
BackgroundCaminiti, S. P., Presotto, L., Baroncini, D., Garibotto, V., Moresco, R. M., Gianolli, L., Volonté, M. A., Antonini, A., & Perani, D. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.03.011 · Cited by 151
Alpha‐synuclein in the appendiceal mucosa of neurologically intact subjects
Gray, M. T., Munoz, D. G., Gray, D. A., Schlossmacher, M. G., & Woulfe, J. M. (2014) · Movement Disorders · doi:10.1002/mds.25779 · Cited by 132
The Role of Microglia in Synaptic Stripping and Synaptic Degeneration: A Revised Perspective
Perry, V. H., & O’Connor, V. (2010) · ASN Neuro · doi:10.1042/an20100024 · Cited by 132
“There are important diseases of the CNS that are associated with the accumulation of misfolded proteins either extracellularly, such as Alzheimer’s disease and prion diseases, or intracellularly, such as Parkinson’s disease and ALS (amyotrophic lateral sclerosis) (Soto, 2003).”
InfluentialKamagata, K., Hatano, T., Okuzumi, A., Motoi, Y., Abe, O., Shimoji, K., Kamiya, K., Suzuki, M., Hori, M., Kumamaru, K. K., et al. (2016) · European Radiology · doi:10.1007/s00330-015-4066-8 · Cited by 135
Adamowicz, D. H., Roy, S., Salmon, D. P., Galasko, D. R., Hansen, L. A., Masliah, E., & Gage, F. H. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3047-16.2016 · Cited by 129
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson’s disease
Zhou, J., Broe, M., Huang, Y. M., Anderson, J. P., Gai, W., Milward, E. A., Porritt, M. J., Howells, D. W., Hughes, A. J., Wang, X., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0815-1 · Cited by 146
“While phosphorylated a-synuclein immunoreactive dotlike structures were identified some time ago in cases with Lewy body formation [34], it has only recently been recognized that these structures are synaptic accumulations of the phosphorylated protein [ 35 , 40].”
BackgroundPathological Influences on Clinical Heterogeneity in Lewy Body Diseases
Coughlin, D. G., Hurtig, H. I., & Irwin, D. J. (2020) · Movement Disorders · doi:10.1002/mds.27867 · Cited by 124
“Synaptic dysfunction from these early SYN species may lead to neuronal dysfunction rather than frank cell death.(83,84) Furthermore, as opposed to the extracellular pathology of tau neurofibrillary ghost tangles left behind from degenerated neurons, LP is cleared after cell death, leaving minimal “ghost” pathology det…”
BackgroundThe Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses
Jan, A., Gonçalves, N. P., Vægter, C. B., Jensen, P. H., & Ferreira, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158338 · Cited by 144
“, impaired redox homeostasis, ionic imbalance and neuroinflammation [13–15]), contribute to the proteopathic stress with detrimental consequences for the neuronal function and/or survival [16,17].”
BackgroundImmunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
“PD results from the death of dopaminergic neurons in the substantia nigra, while in DLB and PDD additional degeneration of cholinergic neurons in the basal forebrain is also observed (Schulz-Schaeffer, 2010; Spillantini & Goedert, 2000).”
BackgroundInteraction between pathogenic proteins in neurodegenerative disorders
Jellinger, K. A. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01507.x · Cited by 128
Synaptic phosphorylated α-synuclein in dementia with Lewy bodies
Colom-Cadena, M., Pegueroles, J., Herrmann, A. G., Henstridge, C. M., Muñoz, L., Querol-Vilaseca, M., Martín-Paniello, C. S., Luque-Cabecerans, J., Clarimon, J., Belbin, O., et al. (2017) · Brain · doi:10.1093/brain/awx275 · Cited by 127
“Taken together, both studies support the notion of small aggregates as key pathological forms in driving synaptic damage and dysfunction (Schulz-Schaeffer, 2010).”
ResultTapias, V., Hu, X., Luk, K. C., Sanders, L. H., Lee, V. M., & Greenamyre, J. T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2541-x · Cited by 126
Synapses and Dendritic Spines as Pathogenic Targets in Alzheimer’s Disease
Yu, W., & Lu, B. (2012) · Neural Plasticity · doi:10.1155/2012/247150 · Cited by 118
Wu, Q., Takano, H., Riddle, D. M., Trojanowski, J. Q., Coulter, D. A., & Lee, V. M.-Y. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0060-19.2019 · Cited by 109
“…is consistent with previous postmortem studies, where nearly 90% of Syn aggregates were located at synapses in the frontal cortex of DLB patients (Schulz-Schaeffer, 2010), and significant synaptic pathology with almost complete loss of dendritic spines were observed at these postsynaptic areas…”
ResultWhat Can We Learn About Human Disease from the Nematode C. elegans?
Apfeld, J., & Alper, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7471-9_4 · Cited by 136
Martin, Z. S., Neugebauer, V., Dineley, K. T., Kayed, R., Zhang, W., Reese, L. C., & Taglialatela, G. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07576.x · Cited by 114
“It also illustrates the importance of determining the effects of extracellular aSyn on neurons, specifically at synapses where aSyn is thought to be released from the aSyn-enriched pre-synaptic terminals (Schulz-Schaeffer 2010).”
InfluentialGuo, Z., Li, M., Li, X., Wang, P., Wang, W., Du, W.-Z., Yang, Z., Chen, S., Wu, D., & Tian, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.745683 · Cited by 116
“Abnormal aggregation of α-synuclein (αS) in the nervous tissue is known to result in neurodegenerative diseases, such as PD (Schulz-Schaeffer 2010).”
BackgroundDiepenbroek, M., Casadei, N., Esmer, H., Saido, T. C., Takano, J., Kahle, P. J., Nixon, R. A., Rao, M. V., Melki, R., Pieri, L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu112 · Cited by 114
Structural and Functional Insights into α-Synuclein Fibril Polymorphism
Mehra, S., Gadhe, L. G., Bera, R., Sawner, A. S., & Maji, S. K. (2021) · Biomolecules · doi:10.3390/biom11101419 · Cited by 117
Synuclein deposition and non-motor symptoms in Parkinson disease
Jellinger, K. A. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.04.012 · Cited by 119
A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy
Richter, F., Fleming, S. M., Watson, M. B., Lemesre, V., Pellegrino, L. J., Ranes, B. E., Zhu, C., Mortazavi, F., Mulligan, C. K., Sioshansi, P. C., et al. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0294-x · Cited by 114
“There is ample evidence that small presynaptic αsynuclein aggregates may be toxic and impair neuronal function, whereas large aggregates in the soma of neurons could be innocuous or protective [41–43].”
BackgroundCarbon nanotubes and graphene as emerging candidates in neuroregeneration and neurodrug delivery
Jaganathan, S. K., John, A., Vellayappan, M. V., Balaji, A., Mohandas, H., & Subramanian, A. P. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s83777 · Cited by 122
The Cell Biology of LRRK2 in Parkinson's Disease
Usmani, A., Shavarebi, F., & Hiniker, A. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00660-20 · Cited by 95
“On a cellular level, surviving neurons in affected regions often contain Lewy bodies and Lewy neurites, cytoplasmic protein aggregates composed predominantly of aggregated a-synuclein (3).”
BackgroundMRI biomarkers of motor and non-motor symptoms in Parkinson's disease
Ryman, S. G., & Poston, K. L. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.10.002 · Cited by 115
Cerebral magnetic resonance elastography in supranuclear palsy and idiopathic Parkinson's disease
Lipp, A., Trbojevic, R., Paul, F., Fehlner, A., Hirsch, S., Scheel, M., Noack, C., Braun, J., & Sack, I. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.09.006 · Cited by 117
“The neuropathology of PD involves presynaptic accumulation of α-synuclein (Cheng et al., 2010; Schulz-Schaeffer, 2010), which starts focally and affects axonal integrity only later in the process of degeneration.”
BackgroundMild Cognitive Impairment in Parkinson’s Disease—What Is It?
Weil, R. S., Costantini, A. A., & Schrag, A. E. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0823-9 · Cited by 109
Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease
Delva, A., Van Weehaeghe, D., Koole, M., Van Laere, K., & Vandenberghe, W. (2020) · Movement Disorders · doi:10.1002/mds.28216 · Cited by 97
The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
Deleersnijder, A., Gérard, M., Debyser, Z., & Baekelandt, V. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.04.002 · Cited by 115
Trudler, D., Sanz-Blasco, S., Eisele, Y. S., Ghatak, S., Bodhinathan, K., Akhtar, M. W., Lynch, W. P., Piña-Crespo, J. C., Talantova, M., Kelly, J. W., et al. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-20.2020 · Cited by 104
Dettmer, U., Ramalingam, N., von Saucken, V. E., Kim, T., Newman, A. J., Terry-Kantor, E., Nuber, S., Ericsson, M., Fanning, S., Bartels, T., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx227 · Cited by 103
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
Visanji, N. P., Lang, A. E., & Kovacs, G. G. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0172-x · Cited by 100
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model
Kohl, Z., Winner, B., Ubhi, K., Rockenstein, E., Mante, M., Münch, M., Barlow, C., Carter, T., Masliah, E., & Winkler, J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07933.x · Cited by 101
“The accumulation of misfolded or mutant alpha-synuclein (a-syn) is one of the major neuropathological hallmarks in Parkinson disease (PD) (Schulz-Schaeffer, 2010).”
BackgroundManzanza, N. D. O., Sedlackova, L., & Kalaria, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690293 · Cited by 101
Lewy body disease or diseases with Lewy bodies?
Menšíková, K., Matěj, R., Colosimo, C., Rosales, R. L., Tučková, L., Ehrmann, J., Hraboš, D., Kolaříková, K., Vodička, R., Vrtěl, R., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-021-00273-9 · Cited by 106
Metadata
- Authors
- Schulz-Schaeffer, W. J.
- Venue
- Acta Neuropathologica
- Published
- 2010-06-20
- Volume
- 120
- Issue
- 2
- Pages
- 131-143
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC2892607
- OpenAlex
- W2033827101
- Cited by
- 627
- References
- 165
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 45 · 2023: 24 · 2022: 43 · 2021: 48 · 2020: 48 · 2019: 41 · 2018: 40 · 2017: 35 · 2016: 36 · 2015: 29 · 2014: 41 · 2013: 36 · 2012: 35
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Funders
- Volkswagen Foundation (ZN 2168)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- alpha-synuclein aggregation, Lewy bodies, dementia with Lewy bodies, Parkinson's disease, Parkinson's disease dementia, presynaptic dysfunction, synaptic pathology, neurotransmitter deficiency, neurodegeneration, trans-synaptic spread, stem cell transplantation, synapse regeneration
- MeSH terms
- Animals, Brain, Parkinson Disease, Synapses, Lewy Body Disease, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.